Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus: a report of three cases

Article Abstract:

The drug tacrolimus may be effective in treating patients with severe systemic lupus erythematosus (SLE) who do not respond to conventional treatment. Three patients with severe inflammation of the blood vessels in the skin due to SLE were treated conventionally and did not respond. Treatment with tacrolimus resulted in control of the disease in two of the patients, at doses of 0.06 milligrams/kilogram/day and 0.18 mg/kg/day, with acceptable side effects. The third patient did not respond, and treatment was discontinued due to kidney toxicity. This apparent success rate of 64% merits further investigation.

Author: Powell, R.J., Duddridge, M.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1997
Evaluation, FK 506

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Is there a future for extracorporeal photochemotherapy in the treatment of the rheumatological diseases?

Article Abstract:

There have been very few studies of extracorporeal photochemotherapy (ECP), but all of them suggest it can be highly beneficial in treating rheumatic diseases. In ECP, after an oral dose of methoxypsoralen, blood is removed, exposed to ultraviolet A light and infused back into the patient. In its first test, 37 patients with cutaneous T cell lymphoma were treated with ECP and 27 improved. Similar positive results were seen in limited studies of rheumatoid arthritis and systemic lupus erythematosus. Large scale controlled trials have yet to be done.

Author: Powell, R.J., Holbrook, M.R.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1997
Usage, Rheumatoid arthritis, Photochemotherapy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use

Article Abstract:

Cyclosporin is not always effective for treating systemic lupus erythematosus. In a study of 43 patients, 83% eventually stopped taking it after a few months either because it wasn't effective or had too many side effects.

Author: Powell, R.J., Morton, S.J.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 2000
Health aspects, Cyclosporine, Cyclosporins

User Contributions:

1
Maria
Report this comment as inappropriate
Sep 1, 2009 @ 3:15 pm
I have a severe case of SLE with APS, kidney failure, and transplant. I have also has heart attack, stroke, liver damage, all this before I was 26...it is under control, I just want to know have there been cases this severe and the patient lived more then 5 or 10 years?

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, Systemic lupus erythematosus
Similar abstracts:
  • Abstracts: Relation between antinuclear antibodies and the autoimmune rheumatic diseases and disease type and activity in systemic lupus erythematosus using a variety of cultured cell lines
  • Abstracts: Relation between antinuclear antibodies and the autoimmune rheumatic diseases and disease type and activity in systemic lupus erythematosus using a variety of cultured cell lines. part 2
  • Abstracts: Acquired C1 inhibitor deficiency associated with systemic lupus erythematosus affecting the central nervous system
  • Abstracts: International Conference Considers Health Needs of the Rural Elderly. Aging prisoners stressing health care system
  • Abstracts: Treatments for wasting in patients with the acquired immunodeficiency syndrome. Metformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.